• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.近十年多发性骨髓瘤患者的生存率显著提高：一项基于瑞典人群研究的结果
Haematologica. 2018 Sep;103(9):e412-e415. doi: 10.3324/haematol.2017.183475. Epub 2018 Mar 22.
2
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.新型疗法时代多发性骨髓瘤患者的生存状况证实了 75 岁以下患者的改善：一项基于人群的分析。
Br J Haematol. 2013 Oct;163(1):40-6. doi: 10.1111/bjh.12465. Epub 2013 Jul 27.
3
Variation in incidence and survival by ethnicity for patients with myeloma in England (2002-2008).英格兰骨髓瘤患者按种族划分的发病率和生存率差异（2002 - 2008年）
Leuk Lymphoma. 2015;56(9):2660-7. doi: 10.3109/10428194.2014.1003060. Epub 2015 Mar 11.
4
Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014.大剂量美法仑自体干细胞移植预处理后多发性骨髓瘤的早期复发疾病：一项基于2005年至2014年丹麦多发性骨髓瘤登记处的研究
Leukemia. 2018 Sep;32(9):2054-2057. doi: 10.1038/s41375-018-0057-5. Epub 2018 Feb 22.
5
Recent improvement in survival of patients with multiple myeloma: variation by ethnicity.多发性骨髓瘤患者生存率的近期改善：按种族划分的差异
Leuk Lymphoma. 2014 May;55(5):1083-9. doi: 10.3109/10428194.2013.827188. Epub 2013 Sep 3.
6
Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups.多发性骨髓瘤患者的疾病特异性生存率：所有年龄组随时间均有显著改善。
Leuk Lymphoma. 2014 Dec;55(12):2850-7. doi: 10.3109/10428194.2014.897700. Epub 2014 May 9.
7
Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades.多发性骨髓瘤患者的生存率有所提高，在三十年的时间里，种族差距逐渐缩小，社会经济地位差距不断扩大。
Leuk Lymphoma. 2018 Jan;59(1):49-58. doi: 10.1080/10428194.2017.1335398. Epub 2017 Jun 9.
8
Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017.多发性骨髓瘤的发病率和生存率：基于人群的研究，纳入了 1982 年至 2017 年期间诊断的 10524 例患者。
Br J Haematol. 2020 Nov;191(3):418-425. doi: 10.1111/bjh.16674. Epub 2020 May 5.
9
The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.合并疾病史对髓系白血病和骨髓瘤全因死亡率及癌症特异性死亡率的影响——一项基于瑞典人群的研究
BMC Cancer. 2015 Nov 5;15:850. doi: 10.1186/s12885-015-1857-x.
10
Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan.真实世界中大型全国健康计划中多发性骨髓瘤患者的流行病学、治疗模式和生存情况。
Leuk Res. 2019 Oct;85:106219. doi: 10.1016/j.leukres.2019.106219. Epub 2019 Aug 23.

引用本文的文献

1
Genetic and Epigenetic Aberrations of in Newly Diagnosed and Relapsed Multiple Myeloma as Well as Related Neoplasms.新诊断及复发的多发性骨髓瘤以及相关肿瘤中的遗传和表观遗传异常
Curr Issues Mol Biol. 2025 Apr 1;47(4):244. doi: 10.3390/cimb47040244.
2
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience.贝兰他单抗莫福汀治疗复发/难治性多发性骨髓瘤患者：一项真实世界经验。
Blood Neoplasia. 2025 Apr 16;2(3):100103. doi: 10.1016/j.bneo.2025.100103. eCollection 2025 Aug.
3
Temporal patterns in US population-based patient survival among adults treated with chemotherapy and/or immunotherapy for multiple myeloma, 2000-2020.2000 - 2020年美国接受化疗和/或免疫疗法治疗的成年多发性骨髓瘤患者基于人群的生存时间模式
Br J Haematol. 2025 Jun 10. doi: 10.1111/bjh.20192.
4
The role of IL-17-related signaling in myelomagenesis, disease prognosis/progression, and therapeutic approach-a scoping review.白细胞介素-17相关信号通路在骨髓瘤发生、疾病预后/进展及治疗方法中的作用——一项综述
Clin Exp Med. 2025 Jun 9;25(1):194. doi: 10.1007/s10238-025-01728-6.
5
MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma: a preliminary study.微小RNA-665及其在多发性骨髓瘤药物反应和生存结局中的潜在作用：一项初步研究
Front Pharmacol. 2025 Apr 4;16:1465814. doi: 10.3389/fphar.2025.1465814. eCollection 2025.
6
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020.抗CD38抗体时代之前接受治疗的新诊断多发性骨髓瘤患者的真实世界结局：2017年至2020年的EMMY队列研究
Cancer Med. 2025 Mar;14(6):e70619. doi: 10.1002/cam4.70619.
7
Evolution of Survival in Patients with Multiple Myeloma over Two Decades: A Real-World Experience from a Medium-Level Hospital.二十年来多发性骨髓瘤患者生存率的演变：来自一家中级医院的真实世界经验。
Cancers (Basel). 2025 Feb 25;17(5):793. doi: 10.3390/cancers17050793.
8
The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone.埃罗妥珠单抗、泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤的真实世界疗效
Hematol Rep. 2024 Sep 30;16(4):593-602. doi: 10.3390/hematolrep16040058.
9
Deep hematologic response to RD treatment in patients with multiple myeloma is associated with overexpression of IL-17R in CD138+ plasma cells.在多发性骨髓瘤患者中，对 RD 治疗的深度血液学反应与 CD138+浆细胞中 IL-17R 的过度表达有关。
Sci Rep. 2024 Oct 9;14(1):23559. doi: 10.1038/s41598-024-74558-3.
10
Multiple myeloma survival in New South Wales, Australia, by treatment era to 2020.澳大利亚新南威尔士州多发性骨髓瘤患者的生存情况，按治疗时期到 2020 年划分。
Cancer Biol Med. 2024 Jul 11;21(8):703-11. doi: 10.20892/j.issn.2095-3941.2024.0177.

本文引用的文献

1
Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.2008-2015 年诊断的骨髓瘤患者的结局和生存情况。来自瑞典骨髓瘤登记处的 4904 例患者的真实世界数据。
Haematologica. 2018 Mar;103(3):506-513. doi: 10.3324/haematol.2017.178103. Epub 2017 Dec 7.
2
Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity.美国多发性骨髓瘤临床试验中未入选患者与参与者之间的差异：对外部有效性的威胁。
Leuk Lymphoma. 2016 Dec;57(12):2827-2832. doi: 10.3109/10428194.2016.1170828. Epub 2016 Apr 22.
3
Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.限制早期死亡率：新诊断多发性骨髓瘤患者管理中的注意事项。
Am J Hematol. 2016 Jan;91(1):101-8. doi: 10.1002/ajh.24129.
4
Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.欧洲 1997 年至 2008 年按地区和年龄划分的血液恶性肿瘤生存情况：基于人群的 EUROCARE-5 研究结果。
Lancet Oncol. 2014 Aug;15(9):931-42. doi: 10.1016/S1470-2045(14)70282-7. Epub 2014 Jul 13.
5
Where we were, where we are, where we are going: progress in multiple myeloma.我们曾在何处、如今身处何方、将去往何处：多发性骨髓瘤的进展
Am Soc Clin Oncol Educ Book. 2014:199-203. doi: 10.14694/EdBook_AM.2014.34.199.
6
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.国际骨髓瘤工作组关于不符合标准自体干细胞移植条件的骨髓瘤患者的管理、治疗和支持性护理的共识声明。
J Clin Oncol. 2014 Feb 20;32(6):587-600. doi: 10.1200/JCO.2013.48.7934. Epub 2014 Jan 13.
7
Improved long-term survival in multiple myeloma up to the age of 80 years.80岁及以下多发性骨髓瘤患者的长期生存率提高。
Leukemia. 2014 Jun;28(6):1346-8. doi: 10.1038/leu.2014.23. Epub 2014 Jan 14.
8
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.多发性骨髓瘤患者的生存率持续提高：老年患者早期死亡率和结局的变化。
Leukemia. 2014 May;28(5):1122-8. doi: 10.1038/leu.2013.313. Epub 2013 Oct 25.
9
Can multiple myeloma become a curable disease?多发性骨髓瘤能成为一种可治愈的疾病吗？
Haematologica. 2011 Sep;96(9):1246-8. doi: 10.3324/haematol.2011.051169.
10
Multiple myeloma.多发性骨髓瘤
N Engl J Med. 2011 Mar 17;364(11):1046-60. doi: 10.1056/NEJMra1011442.

Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.

作者信息

Thorsteinsdottir Sigrun, Dickman Paul W, Landgren Ola, Blimark Cecilie, Hultcrantz Malin, Turesson Ingemar, Björkholm Magnus, Kristinsson Sigurdur Y

机构信息

Department of Internal Medicine, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland.

Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

出版信息

Haematologica. 2018 Sep;103(9):e412-e415. doi: 10.3324/haematol.2017.183475. Epub 2018 Mar 22.

DOI:10.3324/haematol.2017.183475
PMID:29567776
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6119139/
Abstract
摘要